Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Shares Outstanding (Diluted Average) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $72.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 15.42% to $72.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2025, up 15.42% year-over-year, with the annual reading at $72.9 million for FY2025, 15.42% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $72.9 million at Phathom Pharmaceuticals, down from $73.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $73.4 million in Q3 2025, with the low at $38.0 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $55.3 million, with a median of $57.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) skyrocketed 46.27% in 2023, then increased 6.62% in 2024.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $39.1 million in 2022, then surged by 31.11% to $51.3 million in 2023, then rose by 23.18% to $63.2 million in 2024, then rose by 15.42% to $72.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $72.9 million, $73.4 million, and $72.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.